Precision BioSciences, Inc.
DTIL
Rank in Stocks
#16226
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the... Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Share Price
$8.04
Last synced: 2026-11-12
Market Cap
$220.56M
Change (1 day)
-12.13%
Change (1 year)
56.42%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Precision BioSciences, Inc. (DTIL)
Category
Healthcare
EPS for Precision BioSciences, Inc. (DTIL)
EPS as of September 2026 TTM: $-1.23
According to Precision BioSciences, Inc.'s latest financial reports, its current EPS (TTM) is $-1.23. At the end of 2025 the company had an EPS of $-3.56, a decrease compared to its 2024 EPS of $1.05.
EPS history for Precision BioSciences, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.23 | -65.45% |
| 2025 | $-3.56 | -439.05% |
| 2024 | $1.05 | -106.58% |
| 2023 | $-15.96 | -58.11% |
| 2022 | $-38.10 | 144.23% |
| 2021 | $-15.60 | -75.18% |
| 2020 | $-62.85 | 5.63% |
| 2019 | $-59.50 | 111.22% |
| 2018 | $-28.17 | 49.76% |
| 2017 | $-18.81 | 3,738.78% |
| 2016 | $-0.49 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -27.64% |
US
|
|
| $15.66 | -1,373.17% |
US
|
|
| $-7.07 | 474.80% |
US
|
|
| $-5.29 | 330.08% |
AU
|
|
| $12.73 | -1,135.14% |
BE
|
Questions about Precision BioSciences, Inc.'s earnings per share (EPS)
What is Precision BioSciences, Inc.'s earnings per share (EPS)?
Precision BioSciences, Inc.'s earnings per share (EPS) over the last twelve months is $-1.23, as of Sep 2026.
What was Precision BioSciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Precision BioSciences, Inc.'s earnings per share (EPS) was $-3.56, compared with $1.05 in 2024.
How has Precision BioSciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Precision BioSciences, Inc.'s earnings per share (EPS) was highest in 2024 ($1.05) and lowest in 2020 ($-62.85).
How does Precision BioSciences, Inc.'s earnings per share (EPS) compare with similar companies?
Precision BioSciences, Inc.'s earnings per share (EPS) ($-1.23) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.